TP53 and B-cell chronic lymphocytic leukemia: Despite being regarded as equivalent prognostic markers, patients with CLL with a single TP53 abnormality undergoing monotherapy with ibrutinib generally exhibit superior PFS and OS compared to those with multiple TP53 aberrations.